The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.

Post hoc analysis of the randomized clinical trial Vitamin D, Calcium, Lyon Study II (DECALYOS II) to assess effects according to baseline estimated glomerular filtration rate (eGFR).

Why It Was Studied

Studies addressing the effects of vitamin D(3) supplementation on secondary hyperparathyroidism in patients with moderate chronic kidney disease are scarce.

This study included only elderly white women.

Who Took Part

The abstract describes 639 women taking part.

PubMed indexes the participants as people over 80, women only.

Multicenter, randomized, double-blinded, placebo-controlled study of 639 elderly women randomly assigned to calcium-vitamin D(3) fixed combination; calcium plus vitamin D(3) separate combination, or placebo.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

Random assignment meant chance, not the researchers, decided who got Parathyroid Hormone (PTH 1-84) and who got the comparison, which limits bias.

As a double-blind Parathyroid Hormone (PTH 1-84) study, the assignments were hidden from both participants and investigators until the end.

Some women received a placebo instead of Parathyroid Hormone (PTH 1-84), giving a reference point.

More than one site took part, so the women came from several places.

What Was Measured

Studies addressing the effects of vitamin D(3) supplementation on secondary hyperparathyroidism in patients with moderate chronic kidney disease are scarce.

The subject headings attached to it are Calcium, Dietary, Cholecalciferol, Chronic Disease, Dietary Supplements, Hyperparathyroidism, Secondary, Kidney Diseases and Parathyroid Hormone.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 639 women.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (American journal of kidney diseases : the official journal of the National Kidney Foundation), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.